138 related articles for article (PubMed ID: 34619841)
1. [The combination of YAP/TAZ predicts the clinical prognosis in patients with cholangiocarcinoma after radical resection].
Liu Y; Wu Y; Ouyang YS; He JJ; Shen LL; Qi H; Cao F; Chen SG
Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):637-643. PubMed ID: 34619841
[No Abstract] [Full Text] [Related]
2. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma.
Wu H; Liu Y; Jiang XW; Li WF; Guo G; Gong JP; Ding X
Tumour Biol; 2016 Oct; 37(10):13499-13508. PubMed ID: 27465555
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
7. YAP is a critical oncogene in human cholangiocarcinoma.
Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
[TBL] [Abstract][Full Text] [Related]
8. Construction of a prediction model for postoperative prognosis in patients with resectable cholangiocarcinoma based on silence information regulator 2 expression.
Wang W; Ji W; Lyu Z; Sun W; Shao Y; Liu J; Yang Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 53(1):98-107. PubMed ID: 38105682
[TBL] [Abstract][Full Text] [Related]
9. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P; Ercolani C; Di Benedetto A; Pizzuti L; Di Lauro L; Sperati F; Terrenato I; Gamucci T; Natoli C; Di Filippo F; Botti C; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
J Exp Clin Cancer Res; 2016 Apr; 35():62. PubMed ID: 27039292
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression.
Qian M; Yan F; Wang W; Du J; Yuan T; Wu R; Zhao C; Wang J; Lu J; Zhang B; Lin N; Dong X; Dai X; Dong X; Yang B; Zhu H; He Q
Acta Pharm Sin B; 2021 Dec; 11(12):4008-4019. PubMed ID: 35024322
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy.
Yeh CN; Pang ST; Wu RC; Chen TW; Jan YY; Chen MF
Oncol Rep; 2009 Jan; 21(1):49-56. PubMed ID: 19082442
[TBL] [Abstract][Full Text] [Related]
12. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma.
Ilyas SI; Yamada D; Hirsova P; Bronk SF; Werneburg NW; Krishnan A; Salim W; Zhang L; Trushina E; Truty MJ; Gores GJ
J Biol Chem; 2016 Apr; 291(15):8031-47. PubMed ID: 26826125
[TBL] [Abstract][Full Text] [Related]
13. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Serum Platelet-Lymphocyte Ratio as a Prognostic Factor in Cholangiocarcinoma Patients after Radical Resection: A Retrospective Analysis of 119 Patients.
Wu Y; Zhou D; Zhang G; Yi F; Feng L
Gastroenterol Res Pract; 2019; 2019():8506967. PubMed ID: 30809257
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer.
Jiang Y; Xie WJ; Chen RW; You WW; Ye WL; Chen H; Chen WX; Xu JP
Front Surg; 2022; 9():813123. PubMed ID: 35388363
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation.
Smoot RL; Werneburg NW; Sugihara T; Hernandez MC; Yang L; Mehner C; Graham RP; Bronk SF; Truty MJ; Gores GJ
J Cell Biochem; 2018 Jan; 119(1):824-836. PubMed ID: 28661054
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of lymphocyte to monocyte ratio for overall survival in cholangiocarcinoma patients with hepatic resection.
Lv M; Wang K; Zhang Z; Zhang Z; Wan J
Cancer Med; 2023 Apr; 12(8):9482-9495. PubMed ID: 36825605
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
[TBL] [Abstract][Full Text] [Related]
19. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
Ko S; Kim M; Molina L; Sirica AE; Monga SP
Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
[TBL] [Abstract][Full Text] [Related]
20. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
